CYP2D6 gene polymorphism and apatinib affect the metabolic profile of fluvoxamine

This study aimed 1) to investigate the influence of CYP2D6 variants on the catalyzing of fluvoxamine, and 2) to study the interaction between fluvoxamine and apatinib. An enzymatic reaction system was setup and the kinetic profile of CYP2D6 in metabolizing fluvoxamine was determined. In vivo, drug-d...

Full description

Bibliographic Details
Main Authors:	Zhize Ye, Bingbing Chen, Nanyong Gao, Qihui Kong, Xiaoqin Hu, Zhongqiu Lu, Jianchang Qian, Guoxin Hu, Jianping Cai, Bin Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Pharmacology
Subjects:	CYP2D6 fluvoxamine apatinib interaction metabolism
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.985159/full

Similar Items

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism
by: Qi Zhou, et al.
Published: (2023-12-01)

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
by: Zastrozhin MS, et al.
Published: (2018-06-01)

Functional evaluation of cyclosporine metabolism by CYP3A4 variants and potential drug interactions
by: Qihui Kong, et al.
Published: (2023-01-01)

Comparing the Efficacy of Fluvoxamine and Sertraline in Treating Major Depressive Disorder (MDD)
by: Seyed-Saeid Hasani-Tabatabaei, et al.
Published: (2013-12-01)

Prediction of CYP-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Modeling: A Case Study of Salbutamol and Fluvoxamine
by: Lara Marques, et al.
Published: (2023-05-01)

Optimising Fluvoxamine Maternal/Fetal Exposure during Gestation: A Pharmacokinetic Virtual Clinical Trials Study
by: Khairulanwar Burhanuddin, et al.
Published: (2022-12-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Fluvoxamine ameliorates oxidative stress and inflammation induced by bile-duct ligation in male rats
by: Zahra Barmoudeh, et al.
Published: (2022-12-01)

Haloperidol augmentation of fluvoxamine in skin picking disorder: a case report
by: Luca Maria, et al.
Published: (2012-07-01)

Effect of fluvoxamine on plasma interleukin-6 in patients with major depressive disorder: a prospective follow-up study
by: Xueqin Li, et al.
Published: (2023-05-01)

Effect of Fluvoxamine on Electrophysiological and Behavioral Alterations of Rats With Depression
by: Mahsa Rahimi, et al.
Published: (2024-04-01)

Fluvoxamine-induced tics: A rare phenomenon
by: Dimple Gupta, et al.
Published: (2022-01-01)

Sigma-1 Receptor Agonist Fluvoxamine Ameliorates Fibrotic Response of Trabecular Meshwork Cells
by: Judit Hodrea, et al.
Published: (2023-07-01)

A comparison of the anti-anxiety effects of oral ketamine and fluvoxamine in children with separation anxiety disorder manifesting as school refusal
by: Afsaneh Karbasi Amel, et al.
Published: (2023-01-01)

Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial
by: Ramin Hamidi Farahani, et al.
Published: (2023-03-01)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
by: Lishu Yang, et al.
Published: (2018-05-01)

Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats
by: Su-su Bao, et al.
Published: (2023-09-01)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer
by: CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun
Published: (2021-12-01)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
by: Taojun Gong, et al.
Published: (2022-11-01)

Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
by: Mohamed Mahdi, et al.
Published: (2022-03-01)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2020-09-01)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
by: Yingying Du, et al.
Published: (2020-07-01)

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study
by: Estela Pineda, et al.
Published: (2022-11-01)

Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
by: Jian-Guo Zhou, et al.
Published: (2018-09-01)

Prophylactic Gastric Histopathological Evaluation of Fluvoxamine and Mirtazapine in Aspirin Induced Rat Model
by: Shahnaz Fatima, et al.
Published: (2020-12-01)

Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis
by: Li-Chin Lu, et al.
Published: (2022-11-01)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
by: Kenji Hashimoto
Published: (2023-03-01)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
by: Lin-Quan Tang, et al.
Published: (2023-03-01)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
by: Ya-Ya Deng, et al.
Published: (2023-04-01)

Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage
by: WenJuan Wang, et al.
Published: (2024-02-01)

The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial)
by: Taweegrit Siripongboonsitti, et al.
Published: (2023-12-01)

Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project
by: Anaëlle Monfort, et al.
Published: (2023-05-01)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
by: Zhaolun Cai, et al.
Published: (2019-06-01)

Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before–after Analysis
by: Aristotelis Tsiakalos, et al.
Published: (2023-08-01)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
by: Hong-Hong Zhang, et al.
Published: (2022-08-01)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
by: Zhongmian Pan, et al.
Published: (2023-02-01)

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion
by: Lingying Zhao, et al.
Published: (2022-05-01)

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
by: Hu Qiu, et al.
Published: (2023-01-01)

Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trialResearch in context
by: Dhammika Leshan Wannigama, et al.
Published: (2024-04-01)

The Effect of Fluvoxamine on Sex Hormone Levels and Ovarian Histology in Trichogaster trichopterus after Bromocriptine Injection
by: SH Rashidpour, et al.
Published: (2020-12-01)